6 results about "Octreotide" patented technology

The present invention provides a combination of two or more imaging agent conjugates comprising an imaging agent conjugated to a targeting ligand, wherein the imaging agent comprises one or more of: ZW800-1, ZW830-1, ZW700-1-Forte, ZW-DOTA, ZW-PyC3A, ZW-Macropa, ZW-Porphyrin, ZW-NOTA, and ZW-Deferoxamine; and the targeting ligand comprises one or more of: cRGD, dPSMA-617 or KUE, FAP, Bombesin Receptor Binding Vector, or Octreotide Binding Vector, or one or more of the peptides selected from SEQ ID Nos: 1 to 4.

The utility model discloses filling equipment for octreotide microsphere injection, and belongs to the technical field of medicine bottle filling equipment. A visual camera is arranged, the visual camera is used for observing the liquid level in a medicine bottle on a material sliding plate and monitoring the height of the liquid level, a drawing plate is arranged on the material sliding plate in a matched mode, when a defective medicine bottle appears, a driving air cylinder is used for driving the drawing plate to slide, and the defective medicine bottle can be separated from the material sliding plate and slide out of the material sliding plate; and a visual camera is beneficial to improving the consistency of judgment, and the cooperation of a drawing plate and a driving air cylinder is beneficial to quickly removing defective medicines, so that the filling quality of the medicine bottles is greatly improved.

The present invention provides a combination of two or more imaging agent conjugates comprising an imaging agent conjugated to a targeting ligand, wherein the imaging agent comprises one or more of ZW800-1, ZW830-1, ZW700-1-Forte, ZW-DOTA, ZW-PyC3A, ZW-Macropa, ZW-porphyrin, ZW-NOTA, and ZW-Deferoxamine; and the targeting ligand comprises one or more of a cRGD, a dPSMA-617 or a KUE, a FAP, a bombesin receptor binding vector, or a octreotide binding vector, or one or more of peptides selected from SEQ ID No: 1-4.

The invention discloses a pharmaceutical composition for preventing and / or treating acute pancreatitis. The Anarinone root plays a role in preventing and treating acute pancreatitis by inhibiting oxidative stress (such as improving the activity of superoxide dismutase (SOD) and reducing the content of malondialdehyde (MDA)) and / or inhibiting inflammatory response (such as inhibiting activation of an NF-kappa B signal channel and reducing expression of proinflammatory factors such as IL-6, TNF-alpha and the like); compared with a chemical synthetic medicine octreotide (possibly causing gastrointestinal reaction, abnormal blood glucose and other side effects), the long-term use experience of the Anacarid root serving as a traditional habitual natural medicinal material shows that the Anacarid root possibly has better biocompatibility and lower adverse reaction risk, and a possibly safer treatment choice is provided for patients.

The present invention relates to a mixed green solvent based process for the preparation of peptide. More specifically, the present invention relates to a process of the preparation of Octreotide using greener solvent. The process of present invention also focused on minimizing solvent consumption, especially DMF, trifluoroacetic acid (TFA) and ethers. The process of present invention also substitutes acetonitrile with methanol in the chromatographic purification steps. The process of present invention only addresses environmental concerns associated with DMF usage but also maintains the efficiency and effectiveness of the Octreotide synthesis process.

The invention provides a preparation method of several < 68 > Ga labeled somatostatin receptor (SSTR) probes, and belongs to the technical field of nuclear medicine radiopharmaceuticals. The SSTR targeting compound octreotide is structurally modified by changing types and configurations of amino acids, changing disulfide bonds and increasing non-traditional amino acids on the basis of the existing SSTR targeting compound octreotide, and the series of probes have the advantages of good stability, high targeting property, higher tumor / normal tissue ratio (target / non-target ratio) and the like. The invention not only has a good application prospect in the aspect of PET / SPECT (positron emission tomography / single photon emission computed tomography) imaging agents of high-expression SSTR diseases, but also has potential advantages in the aspect of radioactive therapy of SSTR high-expression tumors.